TW201004658A - Nanoparticle compositions for nucleic acids delivery system - Google Patents

Nanoparticle compositions for nucleic acids delivery system Download PDF

Info

Publication number
TW201004658A
TW201004658A TW098125813A TW98125813A TW201004658A TW 201004658 A TW201004658 A TW 201004658A TW 098125813 A TW098125813 A TW 098125813A TW 98125813 A TW98125813 A TW 98125813A TW 201004658 A TW201004658 A TW 201004658A
Authority
TW
Taiwan
Prior art keywords
nanoparticle
peg
lipid
group
oligonucleotide
Prior art date
Application number
TW098125813A
Other languages
English (en)
Chinese (zh)
Inventor
Hong Zhao
lian-jun Shi
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of TW201004658A publication Critical patent/TW201004658A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW098125813A 2008-07-31 2009-07-31 Nanoparticle compositions for nucleic acids delivery system TW201004658A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8528908P 2008-07-31 2008-07-31

Publications (1)

Publication Number Publication Date
TW201004658A true TW201004658A (en) 2010-02-01

Family

ID=41610973

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098125813A TW201004658A (en) 2008-07-31 2009-07-31 Nanoparticle compositions for nucleic acids delivery system

Country Status (6)

Country Link
US (1) US20110111044A1 (enExample)
EP (1) EP2304026A4 (enExample)
JP (1) JP2011529912A (enExample)
CA (1) CA2731173A1 (enExample)
TW (1) TW201004658A (enExample)
WO (1) WO2010014895A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103528A2 (en) * 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
US10081542B2 (en) 2010-04-20 2018-09-25 University of Florida Research Foundation, lnc. Nanozymes, methods of making nanozymes, and methods of using nanozymes
EP2632553B1 (en) 2010-10-28 2020-01-01 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
US8709466B2 (en) 2011-03-31 2014-04-29 International Business Machines Corporation Cationic polymers for antimicrobial applications and delivery of bioactive materials
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9374747B2 (en) * 2012-11-02 2016-06-21 Telefonaktiebolaget Lm Ericsson (Publ) Network node, user node and methods for channel estimation
US9840530B2 (en) * 2013-01-03 2017-12-12 Council Of Scientific & Industrial Research Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
CN104519875A (zh) 2013-08-14 2015-04-15 佛罗里达大学研究基金会公司 纳米酶、制备纳米酶的方法、以及使用纳米酶的方法
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
EP3169335B8 (en) 2014-07-16 2019-10-09 ModernaTX, Inc. Circular polynucleotides
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
WO2017049275A2 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a stabilizing tail region
CN112587504B (zh) * 2016-10-17 2022-10-18 南京绿叶制药有限公司 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
EP3662913A4 (en) * 2017-08-04 2021-06-30 Kyowa Kirin Co., Ltd. Nucleic-acid-containing lipid nanoparticles
EP3740241A1 (en) * 2018-01-18 2020-11-25 eTheRNA Immunotherapies NV Lipid nanoparticles
PT3864163T (pt) 2018-10-09 2024-04-30 Univ British Columbia Composições e sistemas que compreendem vesículas competentes para transfeção isentas de solventes orgânicos e detergentes e métodos relacionados com as mesmas
CN109549934B (zh) * 2018-12-25 2021-03-09 上海交通大学 一种多糖基脂质纳米粒子的制备方法
EP4346781A4 (en) * 2021-06-01 2025-05-07 Nanovation Therapeutics Inc. DNA VECTOR DELIVERY USING LIPID NANOPARTICLES
EP4248949B1 (en) 2022-03-21 2024-08-28 R.G.C.C. Holdings AG Liposomal compositions
CN118922178A (zh) 2022-03-23 2024-11-08 内诺维什疗法股份有限公司 含有高甾醇的脂质纳米颗粒
AU2023244571A1 (en) 2022-04-01 2024-10-10 Nanovation Therapeutics Inc. Mrna delivery method and composition thereof
WO2024085149A1 (ja) * 2022-10-18 2024-04-25 第一三共株式会社 テイラー反応装置及びカプセル粒子の製造方法
WO2025021083A1 (en) * 2023-07-24 2025-01-30 National Institute Of Biological Sciences, Beijing Lipid nanoparticle compositions for localized treatment of skin diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
JP2001508815A (ja) * 1996-05-29 2001-07-03 セル ジェネシス,インコーポレイテッド カチオン性ポリマー/脂質核酸送達ビヒクル
DE69841002D1 (de) * 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080207542A1 (en) * 2002-03-26 2008-08-28 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086883A2 (en) * 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7919466B2 (en) * 2006-02-01 2011-04-05 The Regents Of The University Of California Lymphatic zip codes in tumors and pre-malignant lesions
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
AU2007296055A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties

Also Published As

Publication number Publication date
WO2010014895A2 (en) 2010-02-04
CA2731173A1 (en) 2010-02-04
US20110111044A1 (en) 2011-05-12
WO2010014895A3 (en) 2010-05-27
EP2304026A4 (en) 2013-12-18
JP2011529912A (ja) 2011-12-15
EP2304026A2 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
TW201004658A (en) Nanoparticle compositions for nucleic acids delivery system
TW201019969A (en) Branched cationic lipids for nucleic acids delivery system
US20110305770A1 (en) Releasable polymeric lipids for nucleic acids delivery system
US20110229581A1 (en) Releasable cationic lipids for nucleic acids delivery systems
TW201021852A (en) Releasable fusogenic lipids for nucleic acids delivery systems
AU2019347774A1 (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
CN102231951A (zh) 用于核酸传递系统的可释放的偶联物
EP4497746A1 (en) Novel ionizable lipid and lipid nanoparticle composition using same
US20140080897A1 (en) Hyaluronic acid-nucleic acid conjugate and composition for nucleic acid delivery containing the same
JP5407862B2 (ja) siRNAおよび脂質性4,5−二置換2−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
JP2024541924A (ja) Poegmaベース脂質ナノ粒子
JP6240570B2 (ja) 脂質粒子および核酸送達キャリア
WO2025256540A1 (en) Compositions and method for targeted gene delivery
JP6495995B2 (ja) 脂質粒子および核酸送達キャリア
WO2025167726A1 (zh) 靶向载体、靶向药物及制备方法与应用